

Technology Appraisal Committee A Interests Register

Topic: Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]

Publication Date: 06 August 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Becky Pennington	Committee Member	Indirect – Financial Interests	Becky is in the process of agreeing to advise Amgen on a project in a different disease area: IgG4-RD. It will be an advisory board in mid-October. The drug she working on is not tarlatamab.	26/09/2024	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal.
Dominic Pivonka	Committee Member	Indirect – Financial Interests	<p>Dominic's employer (AbbVie) has a treatment being evaluated for small-cell lung cancer in phase 1</p> <p>The treatment in question is ABBV-706, which is a seizure protein 6 homolog (SEZ6) targeted antibody-drug conjugate being investigated for the treatment of small cell lung cancer, central nervous system tumors and neuroendocrine carcinomas. As it's only in phase 1, it's not in the NICE work programme and it's too early for me to comment on likelihood of Tarlatamab being a comparator in the future.</p>	27/08/2024	It was agreed that Dominic's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor Fiona Blackhall	Clinical Expert	Direct - Financial	Speaker fees and Honoraria for Steering Committee and Advisory Board Roles for Amgen – past four years	08/10/2024	It was agreed that Professor Blacknell's declaration would not prevent her from providing expert advice to the committee.
Dr Yvonne Summers	Clinical Expert	Direct - Financial	<p>Dr Summers received honoraria for advisory work and speaker fees from most of the pharmaceutical companies working in drug development in lung cancer:</p> <ul style="list-style-type: none"> • Support to attend educational conferences from Roche, Takeda • Advisory Board for Amgen, Astra-Zeneca, Bayer, Boehringer Ingelheim, EQRX, Lilly, MSD, Roche, Takeda, Lilly, Pfizer, J&J • Speaker Fees from Amgen, Astra-Zeneca, BMS, Lilly, Sanofi, Takeda 	08/10/2024	It was agreed that Dr Summers' declaration would not prevent her from providing expert advice to the committee.